Integration of organoids in peptide drug discovery: rise of the high-throughput screening

Abstract

Organoids are three-dimensional cell aggregates with near-physiologic cell behaviors and can undergo long-term expansion in vitro. They are amenable to high-throughput drug screening processes, which renders them a viable preclinical model for drug development. The procedure of organoid-based high-throughput screening has been extensively employed to discover small molecule drugs, encompassing the steps of generating organoids, examining efficient drugs in organoid cultures, and data assessment. Compared to small molecules, peptides are more straightforward to synthesize, can be modified chemically, and demonstrate a high degree of target specificity and low cytotoxicity. Therefore, they have emerged as promising carriers to deliver drugs to disease-associated targets, and could be efficient therapeutic drugs for various diseases. To date, organoids have been used to evaluate the efficacy of certain peptide agents; however, no organoid-based high-throughput screening of peptide drugs has been reported. Given the advantages of peptide drugs, there is an urgent need to establish organoid-based peptide high-throughput screening platforms. In this review, we discuss the typical approach of screening small-molecular drugs with the use of organoid cultures, as well as provide an overview of the studies that have incorporated organoids in peptide research. Drawing on the knowledge gained from small molecular screens, we explore the difficulties and potential avenues for creating new platforms to identify peptide agents using organoid models.

Assessment of Fallopian Tube Epithelium Features Derived from Induced Pluripotent Stem Cells of Both Fallopian Tube and Skin Origins

“…They can help identify promising drug candidates and assess their efficacy and safety [28]. Improving the long-term stability of organoids by refining culture methods ensures that organoid models remain relevant and reliable for a wide range of applications, including drug development and therapy testing [29].…”

Stimuli-responsive polymer-based nanosystems for cardiovascular disease theranostics

“…This approach facilitates drug accumulation in pathological tissues of CVDs, thereby improving treatment efficacy while reducing side effects. [154][155][156][157][158][159][160][161] Cholesterol and macrophages are key components of plaque formation that contribute to inflammation in atherosclerotic CVDs. [162][163][164] However, current treatments fail to effectively eliminate these two components from cardiovascular lesions.…”